ZA200402702B - Pharmaceutical composition comprising gamma-butyrobetaine. - Google Patents
Pharmaceutical composition comprising gamma-butyrobetaine. Download PDFInfo
- Publication number
- ZA200402702B ZA200402702B ZA200402702A ZA200402702A ZA200402702B ZA 200402702 B ZA200402702 B ZA 200402702B ZA 200402702 A ZA200402702 A ZA 200402702A ZA 200402702 A ZA200402702 A ZA 200402702A ZA 200402702 B ZA200402702 B ZA 200402702B
- Authority
- ZA
- South Africa
- Prior art keywords
- butyrobetaine
- composition
- gamma
- gbb
- thp
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- JHPNVNIEXXLNTR-UHFFFAOYSA-O 4-(trimethylammonio)butanoic acid Chemical compound C[N+](C)(C)CCCC(O)=O JHPNVNIEXXLNTR-UHFFFAOYSA-O 0.000 title 1
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 claims description 54
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 17
- 230000001568 sexual effect Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 229960003310 sildenafil Drugs 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 5
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 2
- 229960000835 tadalafil Drugs 0.000 claims description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 2
- 229960002381 vardenafil Drugs 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 27
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 10
- 229960001789 papaverine Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000007926 intracavernous injection Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 3
- 230000027326 copulation Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101000912561 Bos taurus Fibrinogen gamma-B chain Proteins 0.000 description 1
- 206010058892 Carnitine deficiency Diseases 0.000 description 1
- JQIYNMYZKRGDFK-RUFWAXPRSA-N Estradiol dipropionate Chemical compound C1CC2=CC(OC(=O)CC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 JQIYNMYZKRGDFK-RUFWAXPRSA-N 0.000 description 1
- 229940122224 Gamma butyrobetaine hydroxylase inhibitor Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical class C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 229950010215 estradiol dipropionate Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960002937 meldonium Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960003207 papaverine hydrochloride Drugs 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-01-134A LV12979B (en) | 2001-09-07 | 2001-09-07 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402702B true ZA200402702B (en) | 2005-05-11 |
Family
ID=19735292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200402702A ZA200402702B (en) | 2001-09-07 | 2004-04-06 | Pharmaceutical composition comprising gamma-butyrobetaine. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20040242590A1 (xx) |
| EP (1) | EP1429753B1 (xx) |
| JP (1) | JP4382480B2 (xx) |
| KR (1) | KR100841035B1 (xx) |
| CN (1) | CN1275595C (xx) |
| AR (1) | AR036423A1 (xx) |
| AT (1) | ATE350029T1 (xx) |
| AU (1) | AU2002236340B2 (xx) |
| BG (1) | BG108673A (xx) |
| CA (1) | CA2459719C (xx) |
| CU (1) | CU23347B6 (xx) |
| DE (1) | DE60217369T2 (xx) |
| DK (1) | DK1429753T3 (xx) |
| EA (1) | EA006675B1 (xx) |
| ES (1) | ES2280505T3 (xx) |
| HK (1) | HK1068003A1 (xx) |
| HR (1) | HRPK20040328B3 (xx) |
| IL (2) | IL160734A0 (xx) |
| JO (1) | JO2507B1 (xx) |
| LV (1) | LV12979B (xx) |
| MA (1) | MA27683A1 (xx) |
| MX (1) | MXPA04002050A (xx) |
| MY (1) | MY134074A (xx) |
| NZ (1) | NZ532178A (xx) |
| PL (1) | PL368758A1 (xx) |
| PT (1) | PT1429753E (xx) |
| SI (1) | SI1429753T1 (xx) |
| TW (1) | TWI224506B (xx) |
| WO (1) | WO2003022262A1 (xx) |
| ZA (1) | ZA200402702B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| LV13450B (en) * | 2004-08-24 | 2006-11-20 | Grindeks As | Novel medicinal use of meldonium and pharmaceutical compositions thereof |
| BRPI0615972A2 (pt) | 2005-07-29 | 2011-05-31 | Concert Pharmaceuticals Inc | composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto |
| WO2009095445A1 (en) * | 2008-01-29 | 2009-08-06 | Grindeks | New second medical use of 3-(2,2,2-trimethylhydrazine)propionate dihydrate |
| CN101781302B (zh) * | 2009-05-31 | 2013-07-10 | 段波 | 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用 |
| RU2622757C1 (ru) * | 2016-06-02 | 2017-06-19 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Способ лечения эректильной дисфункции |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1198434B (it) * | 1981-01-06 | 1988-12-21 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina |
| LV11727B (en) * | 1995-08-21 | 1997-08-20 | Kalvins Ivars | Pharmaceutical composition |
| LV11728B (en) | 1995-08-21 | 1997-08-20 | Kalvins Ivars | Pharmaceutical composition |
-
2001
- 2001-09-07 LV LVP-01-134A patent/LV12979B/en unknown
-
2002
- 2002-03-04 US US10/488,840 patent/US20040242590A1/en not_active Abandoned
- 2002-03-04 MX MXPA04002050A patent/MXPA04002050A/es active IP Right Grant
- 2002-03-04 PL PL02368758A patent/PL368758A1/xx unknown
- 2002-03-04 CN CNB028175077A patent/CN1275595C/zh not_active Expired - Fee Related
- 2002-03-04 AU AU2002236340A patent/AU2002236340B2/en not_active Ceased
- 2002-03-04 EA EA200400386A patent/EA006675B1/ru not_active IP Right Cessation
- 2002-03-04 IL IL16073402A patent/IL160734A0/xx unknown
- 2002-03-04 DE DE60217369T patent/DE60217369T2/de not_active Expired - Lifetime
- 2002-03-04 JP JP2003526391A patent/JP4382480B2/ja not_active Expired - Fee Related
- 2002-03-04 KR KR1020047003366A patent/KR100841035B1/ko not_active IP Right Cessation
- 2002-03-04 ES ES02702955T patent/ES2280505T3/es not_active Expired - Lifetime
- 2002-03-04 CA CA2459719A patent/CA2459719C/en not_active Expired - Fee Related
- 2002-03-04 PT PT02702955T patent/PT1429753E/pt unknown
- 2002-03-04 AT AT02702955T patent/ATE350029T1/de not_active IP Right Cessation
- 2002-03-04 DK DK02702955T patent/DK1429753T3/da active
- 2002-03-04 NZ NZ532178A patent/NZ532178A/en unknown
- 2002-03-04 SI SI200230507T patent/SI1429753T1/sl unknown
- 2002-03-04 EP EP02702955A patent/EP1429753B1/en not_active Expired - Lifetime
- 2002-03-04 WO PCT/LV2002/000004 patent/WO2003022262A1/en active IP Right Grant
- 2002-08-29 MY MYPI20023224A patent/MY134074A/en unknown
- 2002-09-04 AR ARP020103331A patent/AR036423A1/es unknown
- 2002-09-05 TW TW091120239A patent/TWI224506B/zh not_active IP Right Cessation
- 2002-09-05 JO JO200291A patent/JO2507B1/en active
-
2004
- 2004-03-04 IL IL160734A patent/IL160734A/en not_active IP Right Cessation
- 2004-03-04 CU CU20040040A patent/CU23347B6/es unknown
- 2004-04-05 MA MA27608A patent/MA27683A1/fr unknown
- 2004-04-06 ZA ZA200402702A patent/ZA200402702B/en unknown
- 2004-04-07 HR HR20040328A patent/HRPK20040328B3/xx not_active IP Right Cessation
- 2004-04-07 BG BG108673A patent/BG108673A/xx unknown
-
2005
- 2005-01-11 HK HK05100218A patent/HK1068003A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018304380B2 (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same | |
| WO1991007188A1 (en) | Method for reducing blood cholesterol using arginine | |
| KR20070111539A (ko) | 진성 당뇨병 치료용 로플루밀라스트 | |
| US20230149325A1 (en) | Hexylamine salts and methods of using hexylamine | |
| US20030187055A1 (en) | Synergistic pharmaceutical combinations for treating obesity | |
| JP2003171271A (ja) | 耐糖能異常用薬剤 | |
| CA2459719C (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
| AU2002236340A1 (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
| US20040028668A1 (en) | Food supplement with a slimming effect | |
| WO2003022263A1 (en) | Pharmaceutical composition comprising gamma-butyrobetaine for stimulating the sexual activity and potency | |
| RU2790663C1 (ru) | Средство для лечения сердечно-сосудистых и цереброваскулярных заболеваний | |
| WO2017144978A1 (ru) | Соли (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло [3.2.1]октана и оптически активных ацетиламинокислот, их применение для лечения ожирения | |
| JPH0526766B2 (xx) | ||
| JPH06102624B2 (ja) | 非心臓由来の不整脈防止薬 | |
| JPH0440328B2 (xx) | ||
| US3298916A (en) | Treatment and composition for high blood pressure and palpitation | |
| EP1455774A1 (en) | Pharmaceutical composition for treating obesity | |
| EA026727B1 (ru) | Соль (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло[3.2.1]октана и фталевой кислоты, способ её получения, продукт способа, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способы лечения и/или профилактики нарушений, связанных с ожирением | |
| WO2016075539A1 (ru) | Композиция для лечения нарушений, связанных с избыточным весом или ожирением | |
| UA48470A (uk) | Біологічно активний препарат "кардонат" |